USH1649H - HIV protease inhibitor combinations - Google Patents

HIV protease inhibitor combinations Download PDF

Info

Publication number
USH1649H
USH1649H US08/436,868 US43686895A USH1649H US H1649 H USH1649 H US H1649H US 43686895 A US43686895 A US 43686895A US H1649 H USH1649 H US H1649H
Authority
US
United States
Prior art keywords
pharmaceutically acceptable
formula
compound
acceptable derivative
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US08/436,868
Other languages
English (en)
Inventor
Joel C. Barrish
Richard J. Colonno
Pin-Fang M. Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US08/436,868 priority Critical patent/USH1649H/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COLONNO, RICHARD J., LIN, PIN-FANG M., BARRISH, JOEL C.
Priority to JP7169630A priority patent/JPH08109131A/ja
Priority to EP95304718A priority patent/EP0691345A3/en
Priority to CA002153270A priority patent/CA2153270A1/en
Application granted granted Critical
Publication of USH1649H publication Critical patent/USH1649H/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds

Definitions

  • the present invention relates to combinations of antiviral agents. More particularly, it relates to combinations of HIV-1 protease inhibitors which exhibit lack of cross-resistance and are thus desirable in the clinical treatment of HIV infection.
  • HIV-1 Human Immunodeficiency Virus
  • Retrovir® zidovudine; Retrovir®
  • DDI didanosine, Videx®
  • DDC zalcitabine, Hivid®
  • the HIV-1 reverse transcriptase has proven to be a very accommodating enzyme that is capable of harboring several amino acid substitutions that render it resistant to individual nucleoside analogs or a combination of nucleoside and/or non-nucleoside analogs.
  • HIV-1 also encodes an aspartyl protease enzyme that plays an essential role in reproduction of the virus late in infection and represents an attractive target for drug intervention. Recently, several inhibitors of this protease have been reported in the literature. Since these protease inhibitors, unlike reverse transcriptase inhibitors, have the ability to inhibit the production of infectious virus particles in chronically-infected cells, they are promising candidates for anti-HIV therapy.
  • D a and D b are independently selected from groups of the formula: ##STR3## where D a and D b are bonded to the groups A a and A b , respectively, through the moiety --E--N(R 8 )--, where E is a single bond or a peptide chain containing 1 to 4 amino acids, the N-terminus of which is bonded to A a when E is part of D a or to A b when E is part of D b ;
  • R 1 and R 2 are independently:
  • R 3 and R 4 are independently:
  • alkyl especially lower alkyl
  • R 3 and R 4 when R 3 and R 4 are bonded to a common nitrogen atom, R 3 and R 4 may be joined, together with that nitrogen atom, to form a heterocyclic ring system, such as a 5 to 7 membered heterocyclic ring; or
  • R 3 when E is a single bond and R 3 is part of A a or A b , R 3 may, together with R 8 , form an alkylene group, for example, having one to five carbons, such as wherein R 3 and R 8 , together with the atoms to which they are bonded, form the cyclic moiety: ##STR4##
  • R 5 , R 6 and R 7 are independently: (a) hydrogen;
  • R 5 , R 6 and R 7 may, independently, be joined, together with the carbon atom to which they are bonded, to form a mono-, bi- or tricyclic carbocyclic ring system, especially wherein each ring contains 3 to 7 carbon atoms, or a mono-, bi- or tricyclic heterocyclic ring system;
  • R 5 , R 6 and R 7 when E is a single bond and R 5 , R 6 and R 7 are part of A a or A b , one of R 5 , R 6 , or R 7 may, together with R 8 , form an alkylene group, for example, having one to three carbons, such as wherein R 5 and R 6 are methyl and R 7 and R 8 , together with the atoms to which they are bonded, form the cyclic moiety: ##STR5##
  • R 8 is: (a) hydrogen;
  • alkyl especially unsubstituted lower alkyl or aryl-lower alkyl
  • R 8 and R 9 may be joined, together with the atoms to which they are bonded, to form a heterocyclic ring system, for example, a 5 to 7 membered monocyclic heterocyclic ring;
  • R 8 may be joined together with R 5 , R 6 or R 7 as described above;
  • R 8 may be joined together with R 3 as described above;
  • R 8 and R 11 may be joined, together with the atoms to which they are bonded, to form a heterocyclic ring system, such as where R 8 and R 11 together are an alkylene group;
  • R 9 and R 9' are independently:
  • R 9 may be joined together with R 8 as described above;
  • R 9 and R 9' may be joined, together with the carbon atom to which they are bonded, to form a carbocyclic group, such as 5- or 6-membered carbocyclic ring;
  • R 10 is:
  • alkyl such as unsubstituted lower alkyl or hydroxy-lower alkyl, cycloalkyl-lower alkyl, aryl-lower alkyl or heterocyclo-lower alkyl;
  • R l0 and R 11 taken together may form a bond to give a keto (C ⁇ O) group
  • R 11 is:
  • R 11 may be joined together with R 8 as described above;
  • R 11 may, together with R 10 , form a bond to give a keto group as described above;
  • Z is oxygen or sulfur; and p and q are, independently, integers from 0 to 4; and salts, preferably pharmaceutically acceptable salts, thereof.
  • BMS-186318 include the pharmaceutically acceptable salts formed with inorganic and/or organic acids, e.g. succinic acid, acetic acid, hydrochloric acid, fumaric acid, citric acid, malic acid, methanesulfonic acid, benzenesulfonic acid, phosphoric acid, maleic acid and tartaric acid.
  • the succinate salt of BMS-186318 is a particularly preferred embodiment.
  • EP 432695 A2 discloses the Hoffmann-LaRoche HIV-1 protease inhibitor of the formula ##STR7## which is known as saquinavir or Ro 31-8959.
  • This compound has the chemical name N-tert.butyl-decahydro-2(2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl)amino)butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide.
  • PCT Published Application WO 92/08688 discloses the Monsanto-Searle HIV-1 protease inhibitor designated SC-52151 having the formula ##STR8## and the chemical name [1S-[1R*(R*), 2S*]]-N 1 [3-[[[(1,1-dimethylethyl)amino]-carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide.
  • EP 402646 A1 discloses the Abbott HIV-1 protease inhibitor designated A-77003 having the formula ##STR9## and the chemical name (2S,3R,4S,5S)-2,5-di-(N-((N-methyl-N-((2-pyridinyl)methyl)amino)carbonyl)-valinyl-amino)-3,4-dihydroxy-1,6-diphenylhexane.
  • the Abbott HIV-1 protease inhibitor designated ABT-538 having the formula ##STR10## and the chemical name, [1S-(1R,2R,4R)]-N-[2-hydroxy-5-phenyl-1-(phenylmethyl)-1-[[(5-thiazolylmethoxy)carbonyl]amino]pentyl]-N 2 -[[N-methyl[[2-(1-methylethyl)-4-thiazolyl]methyl]amino]carbonyl]L-valinamide, is generically disclosed in EP 486948 A2 and specifically disclosed in an abstract for the 207th American Chemical Society meeting (Mar. 13-17, 1994) held in San Diego, Calif.
  • EP 486948 A2 discloses the Abbott HIV-1 protease inhibitor designated A-80987 having the formula ##STR11## and the chemical name (2S,3S,5S)-2-(N-(N-((2-pyridinyl)methoxycarbonyl)-valinyl)amino)-5-(N-((3-pyridinyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane.
  • EP 541168 A1 discloses the Merck HIV-1 protease inhibitor designated L-735,524 having the formula ##STR12## and the chemical name N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide.
  • AG-1343 may be prepared by reacting the amine of the formula ##STR14## (prepared as described in Jungheim, et al., European Published Application 604,185A1) with the acid ##STR15## (prepared as described in U.S. Pat. No. 5,110,979; Houbion, et al. in Org. Prep. Proced. Int., 1979, 11, 27; and Cresp, et al., in J. Chem. Soc. Perkins Trans. I, 1974, 2435) under standard peptide coupling conditions, e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide(EDC)/hydroxybenzotriazole (HOBT).
  • peptide coupling conditions e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide(EDC)/hydroxybenzotriazole (HOBT).
  • this invention provides pharmaceutical compositions for prophylaxis or treatment of diseases caused by the HIV virus comprising an effective HIV-inhibiting amount of BMS-186318 having the formula ##STR16## or a pharmaceutically acceptable derivative thereof, and an effective HIV-inhibiting amount of one or more HIV-1 protease inhibitors selected from the group consisting of (a) Ro 31-8959 having the formula ##STR17## or a pharmaceutically acceptable derivative thereof, (b) SC-52151 having the formula ##STR18## or a pharmaceutically acceptable derivative thereof, (c) A-77003 having the formula ##STR19## or a pharmaceutically acceptable derivative thereof, (d) A-80987 having the formula ##STR20## or a pharmaceutically acceptable derivative thereof, (e) L-735,524 having the formula ##STR21## or a pharmaceutically acceptable derivative thereof, (f) ABT-538 having the formula ##STR22## or a pharmaceutically acceptable derivative thereof, and (g) AG-1343 having the formula ##STR23## or a pharmaceutically acceptable derivative thereof, and
  • the present invention provides a method for the prophylaxis or treatment of diseases caused by the HIV virus in a human patient, which comprises administering to said patient, either sequentially or concurrently, an effective HIV-inhibiting amount of BMS-186318 having the formula ##STR24## or a pharmaceutically acceptable derivative thereof, and an effective HIV-inhibiting amount of one or more HIV-1 protease inhibitors selected from (a) Ro 31-8959 having the formula ##STR25## or a pharmaceutically acceptable derivative thereof, (b) SC-52151 having the formula, ##STR26## or a pharmaceutically acceptable derivative thereof, (c) A-77003 having the formula ##STR27## or a pharmaceutically acceptable derivative thereof, (d) A-80987 having the formula ##STR28## or a pharmaceutically acceptable derivative thereof, (e) ABT-538 having the formula ##STR29## or a pharmaceutically acceptable derivative thereof, (f) L-735,524 having the formula ##STR30## or a pharmaceutically acceptable derivative thereof, and (g) AG-13
  • the present invention provides a method for reducing or eliminating resistance resulting from administration of an HIV-1 protease inhibitor selected from the group consisting of (a) Ro 31-8959, or a pharmaceutically acceptable derivative thereof, (b) SC-52151, or a pharmaceutically acceptable derivative thereof, (c) A-77003, or a pharmaceutically acceptable derivative thereof, (d) A-80987, or a pharmaceutically acceptable derivative thereof, (e) ABT-538, or a pharmaceutically acceptable derivative thereof, (f) L-735,524, or a pharmaceutically acceptable derivative thereof, and (g) AG-1343, or a pharmaceutically acceptable derivative thereof, or a combination of two or more of said inhibitors, which comprises administering either sequentially or concurrently, an effective HIV-inhibiting amount of BMS-186318, or a pharmaceutically acceptable derivative thereof.
  • an HIV-1 protease inhibitor selected from the group consisting of (a) Ro 31-8959, or a pharmaceutically acceptable derivative thereof, (b) SC-52151, or a pharmaceutically acceptable derivative thereof,
  • BMS-186318 included within the scope of general formula I and specifically disclosed in Example 226 of our parent application, exhibits unexpected advantages when used in combination with certain other HIV-1 protease inhibitors.
  • BMS 186,318 displays a synergistic antiviral effect in cell culture assays when used in combination with either Ro 31-8959 or SC-52151.
  • Second, HIV-1 variants resistant to BMS 186,318 remain susceptible to inhibition by the other protease inhibitors. The surprising lack of cross-resistance seen with these combinations would be an important clinical advance in the treatment of diseases caused by HIV.
  • a pharmaceutically acceptable derivative as used herein is meant to include any pharmaceutically acceptable salt, prodrug or solvate of a compound of the present invention which, upon administration to the host, is capable of providing (directly or indirectly) the parent compound or an antivirally effective metabolite or residue thereof.
  • pharmaceutically acceptable salt denotes pharmaceutically acceptable acidic salts formed with inorganic and/or organic acids. Suitable pharmaceutically acceptable salts of the HIV-1 protease inhibitor compounds of the present invention are disclosed in EP 580402 A2, EP 432695 A2, WO 92/08688, EP 402646 A1, EP 486948 A2 and EP 541168 A1.
  • Such salts are acid addition salts formed from inorganic acids such as hydrochloric acid, hydrobromic, nitric acid, sulfuric acid and phosphoric acid and organic acids such as oxalic acid, acetic acid, maleic acid, lactic acid, glycolic acid, tartaric acid, succinic acid, methanesulfonic acid and citric acid.
  • inorganic acids such as hydrochloric acid, hydrobromic, nitric acid, sulfuric acid and phosphoric acid
  • organic acids such as oxalic acid, acetic acid, maleic acid, lactic acid, glycolic acid, tartaric acid, succinic acid, methanesulfonic acid and citric acid.
  • solvate is meant to include both hydrates and solvates with organic solvents.
  • the solvates are hydrates.
  • Prodrugs of the HIV inhibitor compounds are also contemplated.
  • the term "prodrug” as used herein denotes a compound which, upon administration to a patient, undergoes chemical conversion by metabolic or chemical processes to yield the parent compound, or a salt or solvate thereof. See H. Bundgaard, “Drugs of the Future", 16(5), 443-458 (1991) and H. Bundgaard(Ed.), “Design of Prodrugs", 1985 Elsevier (Amsterdam), both incorporated herein by reference.
  • Example 1 A method for preparing BMS-186318 is disclosed below in Example 1. Methods for preparing the other HIV-1 protease inhibitors encompassed by the present invention are disclosed in the references disclosed above in connection with pharmaceutically acceptable salts and with AG-1343.
  • the BMS-186318 and the other HIV-1 protease inhibitor(s) may be administered either simultaneously (either separately or in combination) or sequentially. If administration is sequential, the delay in administering the active ingredients should not be such as to lose the benefit of the advantageous effect of the combination. Preferably, administration will be simultaneous.
  • Each compound is employed in the combination in an amount at which it exhibits HIV-inhibitory activity when used alone. Suitable dosage ranges are disclosed in the literature, e.g. see the patent references indicated above in connection with pharmaceutically acceptable salts.
  • BMS-186318 may be administered in a total daily dosage of from about 1 to 150 mg/kg of body weight, preferably about 10 to 50 mg/kg of body weight.
  • Ro 31-8959 may be administered in a daily dosage of from about 3 mg to about 3 grams, preferably about 10 mg to 1 gram.
  • SC-52151 may be administered in a total daily dose of from about 0.001 to 10 mg/kg body weight, preferably 0.01 to 1 mg/kg.
  • A-77003 may be administered in a daily dosage of from about 0.001 to 10 mg/kg, preferably 0.01 to 1 mg/kg of body weight.
  • A-80987 may be administered in a total daily dose of from about 0.001 to 300 mg/kg body weight, preferably 0.1 to 10 mg/kg.
  • L-735,524 may be administered in a total daily dosage of from about 0.02 to 10 grams.
  • ABT-538 may be administered in a total daily dosage of from about 0.001 to 300 mg/kg of body weight.
  • AG-1343 may be administered in a total daily dosage of from about 100 mg to 2000 mg.
  • a suitable daily dose will be in the range of from about 0.001 to about 300 mg/kg of body weight for each compound.
  • a preferred dosage range would be in the range of between about 1 and about 50 mg/kg of body weight per day, administered as a single dose or in the form of individual divided doses, such as from 1-4 times per day.
  • compositions of the present invention may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration.
  • the compounds may, for example, be administered orally, such as in the form of tablets, capsules, granules or powders; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (e.g.
  • aqueous or non-aqueous solutions or suspension examples include topically, such as in the form of ointments, creams or lotions, or as a transdermal patch, or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents.
  • the compounds may, for example, be administered liposomally.
  • compositions When administered orally, the compositions may be prepared by techniques well-known in the art of pharmaceutical formulation. As a suspension they may, for example, contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents known in the art. As immediate release tablets, the present compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
  • compositions When administered as injectable solutions or suspensions, the present compositions may be formulated according to techniques well-known in the pharmaceutical art, using suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides and fatty acids, including oleic acid.
  • suitable non-toxic, parenterally acceptable diluents or solvents such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides and fatty acids, including oleic acid.
  • compositions When rectally administered in the form of suppositories, these compositions may be prepared by techniques well-known in the pharmaceutical art by mixing the drug with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.
  • a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.
  • compositions may be formulated as lotions, ointments or creams, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • Formulations suitable for topical administration to the mouth include lozenges, comprising active ingredient in a flavored base, usually sucrose and acacia or tragacanth; pastilles containing the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • compositions of the present invention are useful in the inhibition of HIV protease, and thus in the prevention and/or treatment of infections caused by HIV viruses (HIV-1, HIV-2, and mutants thereof), including the treatment of consequent pathological conditions such as AIDS.
  • HIV viruses HIV-1, HIV-2, and mutants thereof
  • compositions of the present invention in inhibiting HIV protease includes, but is not limited to, treating a wide range of states of HIV infection such as treating or preventing AIDS or ARC (AIDS related complex), treating both symptomatic and asymptomatic HIV-infected patients, and treating actual or potential exposure to HIV.
  • the compositions of the present invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g. blood transfusion, accidental needle stick, or exposure to patient blood during surgery.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US08/436,868 1987-07-31 1995-05-17 HIV protease inhibitor combinations Abandoned USH1649H (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/436,868 USH1649H (en) 1987-07-31 1995-05-17 HIV protease inhibitor combinations
JP7169630A JPH08109131A (ja) 1994-07-05 1995-07-05 Ｈｉｖプロテアーゼ抑制因子組成物
EP95304718A EP0691345A3 (en) 1994-07-05 1995-07-05 Combinations of HIV protease inhibitors
CA002153270A CA2153270A1 (en) 1994-07-05 1995-07-05 Hiv protease inhibitor combinations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7997887A 1987-07-31 1987-07-31
US27061494A 1994-07-05 1994-07-05
US08/436,868 USH1649H (en) 1987-07-31 1995-05-17 HIV protease inhibitor combinations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US27061494A Continuation-In-Part 1987-07-31 1994-07-05

Publications (1)

Publication Number Publication Date
USH1649H true USH1649H (en) 1997-05-06

Family

ID=26954391

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/436,868 Abandoned USH1649H (en) 1987-07-31 1995-05-17 HIV protease inhibitor combinations

Country Status (4)

Country Link
US (1) USH1649H (ja)
EP (1) EP0691345A3 (ja)
JP (1) JPH08109131A (ja)
CA (1) CA2153270A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100277A (en) * 1994-06-03 2000-08-08 G.D. Searle & Co. Retroviral protease inhibitor combinations
US6538006B1 (en) 1998-07-08 2003-03-25 Pharmacia Corporation Retroviral protease inhibitors
US20060240410A1 (en) * 1994-06-03 2006-10-26 G.D. Searle & Co. Retroviral protease inhibitor combinations
WO2007094983A2 (en) * 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
USRE42889E1 (en) 1992-08-25 2011-11-01 G.D. Searle Llc α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
USRE43596E1 (en) 1992-08-25 2012-08-21 G.D. Searle Llc α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2242761A1 (en) * 1996-01-26 1997-07-31 William W. Freimuth Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6737264B1 (en) 1999-01-21 2004-05-18 Kaneka Corporation Method for purifying and isolating (2s,3s)- or (2r,3s)-halohydrin derivatives
CA2417127A1 (en) * 2000-07-24 2002-01-31 The University Of Queensland Compounds and inhibitors of phospholipases
US7122696B2 (en) 2000-11-30 2006-10-17 Ajinomoto Co., Inc. Processes for preparation of N-protected-β-amino alcohols and N-protected-β-amino epoxides
WO2003091233A1 (fr) * 2002-04-26 2003-11-06 Ajinomoto Co., Inc. Procede de production d'aminoepoxyde
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580402A2 (en) * 1992-07-20 1994-01-26 E.R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
FR2490872A1 (fr) 1980-09-19 1982-03-26 Thomson Csf Ligne a retard a cavites couplees pour tube a ondes progressives et tube a ondes progressives comportant une telle ligne
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
EP0558603B1 (en) * 1990-11-19 1998-08-26 Monsanto Company Retroviral protease inhibitors
IE20010533A1 (en) * 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
US5110979A (en) 1991-01-15 1992-05-05 Imperial Chemical Industries Plc Trisubstituted benzoic acid intermediates
DK0541168T3 (da) * 1991-11-08 1998-05-11 Merck & Co Inc HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
WO1994002149A1 (en) 1992-07-17 1994-02-03 The General Hospital Corporation Convergent combination anti-viral therapy
MX9308016A (es) 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
JP4369973B2 (ja) 2007-12-27 2009-11-25 株式会社日本製鋼所 カッタ装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580402A2 (en) * 1992-07-20 1994-01-26 E.R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. pillay et al., "HIV-1 Protease Inhibitors: . . . Clin. Potential", Rev. Med. Virol., vol. 5, pp. 23-33.
D. pillay et al., HIV 1 Protease Inhibitors: . . . Clin. Potential , Rev. Med. Virol., vol. 5, pp. 23 33. *
HIV 1 Protease Inhibitors: Their Development, Mechanism of Action and Clinical Potential, D. Pillay et al, Rev. Med. Virol. , 5: 23 33, 1995. *
HIV-1 Protease Inhibitors: Their Development, Mechanism of Action and Clinical Potential, D. Pillay et al, Rev. Med. Virol., 5: 23-33, 1995.

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42889E1 (en) 1992-08-25 2011-11-01 G.D. Searle Llc α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
USRE43596E1 (en) 1992-08-25 2012-08-21 G.D. Searle Llc α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
USRE43802E1 (en) 1992-08-25 2012-11-13 G.D. Searle Llc α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6100277A (en) * 1994-06-03 2000-08-08 G.D. Searle & Co. Retroviral protease inhibitor combinations
US20060240410A1 (en) * 1994-06-03 2006-10-26 G.D. Searle & Co. Retroviral protease inhibitor combinations
US6538006B1 (en) 1998-07-08 2003-03-25 Pharmacia Corporation Retroviral protease inhibitors
US7026333B1 (en) 1998-07-08 2006-04-11 G. D. Searle & Co. Retroviral protease inhibitors
WO2007094983A2 (en) * 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
WO2007094983A3 (en) * 2006-02-03 2007-12-06 Tanox Inc Methods and compositions for the inhibition of hiv infection of t cells

Also Published As

Publication number Publication date
JPH08109131A (ja) 1996-04-30
EP0691345A2 (en) 1996-01-10
CA2153270A1 (en) 1996-01-06
EP0691345A3 (en) 1996-02-28

Similar Documents

Publication Publication Date Title
EP1302468B1 (en) Processes and intermediates for manufacturing retroviral protease inhibiting compounds
USH1649H (en) HIV protease inhibitor combinations
KR100520737B1 (ko) 아스파틸 프로테아제 억제제의 전구약물로서 술폰아미드유도체
US6037157A (en) Method for improving pharmacokinetics
DE69534549T2 (de) Kombination von retroviralen Proteasehemmern
EP0735019B1 (en) Retroviral protease inhibitors
CZ176298A3 (cs) Sloučeniny inhibující proteázy retrovirů
SK52394A3 (en) Hiv protease inhibitors useful for the treatment of aids
PL187747B1 (pl) Zastosowanie sulfonamidowego inhibitora proteazy HIV
WO1992017176A1 (en) Retroviral protease inhibiting compounds
US20080125467A1 (en) Amino-Containing Compounds Which Inhibit Memapsin 2 Beta-Secretase Activity and Methods of Use Thereof
CA3095164A1 (en) Calpain modulators and therapeutic uses thereof
JP2012528160A (ja) Ｈｉｖプロテアーゼ阻害薬
US6673821B2 (en) Nitrogen heterocycle inhibitors of aspartyl protease
US20130274254A1 (en) Inhibitors of cytochrome p450 (cyp3a4)
KR20010032055A (ko) Ａｉｄｓ 치료를 위한 혼합물 치료방법
EP3778577B1 (en) Novel compound exhibiting enteropeptidase inhibitory activity
TWI292752B (en) Retroviral protease inhibiting compounds
JP2004043324A (ja) 芳香族アミン化合物及びその用途
MXPA00006315A (en) Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
MXPA00011244A (en) Retroviral protease inhibiting compounds
MXPA00006316A (es) Profarmacos de inhibidores de aspartil proteasa
JP2003504383A (ja) アルファ−ヒドロキシ−ガンマ−［［（炭素環式−又はヘテロ環式−置換）アミノ］カルボニル］アルカンアミド誘導体及びこれらの使用

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARRISH, JOEL C.;COLONNO, RICHARD J.;LIN, PIN-FANG M.;REEL/FRAME:007665/0003;SIGNING DATES FROM 19950510 TO 19950515

STCF Information on status: patent grant

Free format text: PATENTED CASE